Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Corcept Therapeutics

    NASDAQ: CORT · Real-Time Price · USD
    70.84
    0.78 (1.11%)
    At close: Jun 16, 2025, 3:59 PM
    70.36
    -0.68%
    Pre-market: Jun 17, 2025, 06:11 AM EDT

    Corcept Therapeutics Statistics

    Share Statistics

    Corcept Therapeutics has 106.05M shares outstanding. The number of shares has increased by 1.34% in one year.

    Shares Outstanding

    n/a
    		 106.05M

    Shares Change (YoY)

    n/a
    		 1.34%

    Shares Change (QoQ)

    n/a
    		 0.69%

    Owned by Institutions (%)

    n/a
    		 81.51%

    Shares Floating

    n/a
    		 93.8M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,606

    FTD / Avg. Volume

    n/a
    		 0.15%

    Short Selling Information

    The latest short interest is 12.64M, so 11.92% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 12.64M

    Short % of Shares Out

    n/a
    		 11.92%

    Short % of Float

    n/a
    		 16.06%

    Short Ratio (days to cover)

    n/a
    		 11.89

    Valuation Ratios

    The PE ratio is 37.23 and the forward PE ratio is 26.36. Corcept Therapeutics's PEG ratio is 1.15.

    PE Ratio

    n/a
    		 37.23

    Forward PE

    n/a
    		 26.36

    PS Ratio

    n/a
    		 7.71

    Forward PS

    n/a
    		 2.8

    PB Ratio

    n/a
    		 7.65

    P/FCF Ratio

    n/a
    		 26.55

    PEG Ratio

    n/a
    		 1.15
    Financial Ratio History

    Enterprise Valuation

    Corcept Therapeutics has an Enterprise Value (EV) of 5.08B.

    EV / Sales

    n/a
    		 7.53

    EV / EBITDA

    n/a
    		 37.1

    EV / EBIT

    n/a
    		 25.65

    EV / FCF

    n/a
    		 25.94

    Financial Position

    The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 3.35

    Quick Ratio

    n/a
    		 3.26

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 0.05

    Debt / FCF

    n/a
    		 0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 20.56% and Return on Invested Capital is 17.09%.

    Return on Equity

    n/a
    		 20.56%

    Return on Assets

    n/a
    		 16.62%

    Return on Invested Capital

    n/a
    		 17.09%

    Revenue Per Employee

    n/a
    		 $1,350,080

    Profits Per Employee

    n/a
    		 $279,466

    Employee Count

    n/a
    		 500

    Asset Turnover

    n/a
    		 0.8

    Inventory Turnover

    n/a
    		 0.88

    Taxes

    Income Tax

    n/a
    		 20.28M

    Effective Tax Rate

    n/a
    		 12.56%

    Stock Price Statistics

    The stock price has increased by 147.78% in the last 52 weeks. The beta is 0.18, so Corcept Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.18

    52-Week Price Change

    n/a
    		 147.78%

    50-Day Moving Average

    n/a
    		 71.59

    200-Day Moving Average

    n/a
    		 58.64

    Relative Strength Index (RSI)

    n/a
    		 46.95

    Average Volume (20 Days)

    n/a
    		 1,689,093

    Income Statement

    In the last 12 months, Corcept Therapeutics had revenue of 675.04M and earned 139.73M in profits. Earnings per share was 1.35.

    Revenue

    n/a
    		 675.04M

    Gross Profit

    n/a
    		 664.16M

    Operating Income

    n/a
    		 136.95M

    Net Income

    n/a
    		 139.73M

    EBITDA

    n/a
    		 136.95M

    EBIT

    n/a
    		 136.95M

    Earnings Per Share (EPS)

    n/a
    		 1.35
    Full Income Statement

    Balance Sheet

    The company has 127.67M in cash and 6.94M in debt, giving a net cash position of 120.73M.

    Cash & Cash Equivalents

    n/a
    		 127.67M

    Total Debt

    n/a
    		 6.94M

    Net Cash

    n/a
    		 120.73M

    Retained Earnings

    n/a
    		 543.74M

    Total Assets

    n/a
    		 846.46M

    Working Capital

    n/a
    		 295.44M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 198.07M and capital expenditures -2.17M, giving a free cash flow of 195.9M.

    Operating Cash Flow

    n/a
    		 198.07M

    Capital Expenditures

    n/a
    		 -2.17M

    Free Cash Flow

    n/a
    		 195.9M

    FCF Per Share

    n/a
    		 1.9
    Full Cash Flow Statement

    Margins

    Gross margin is 98.39%, with operating and profit margins of 20.29% and 20.7%.

    Gross Margin

    n/a
    		 98.39%

    Operating Margin

    n/a
    		 20.29%

    Pretax Margin

    n/a
    		 23.92%

    Profit Margin

    n/a
    		 20.7%

    EBITDA Margin

    n/a
    		 20.29%

    EBIT Margin

    n/a
    		 20.29%

    FCF Margin

    n/a
    		 29.02%

    Dividends & Yields

    CORT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 2.69%

    FCF Yield

    n/a
    		 3.77%
    Dividend Details

    Analyst Forecast

    The average price target for CORT is $143.5, which is 102.6% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $143.5

    Price Target Difference

    n/a
    		 102.6%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $10.76

    Lynch Upside

    n/a
    		 -84.81%

    Graham Number

    n/a
    		 14.16

    Graham Upside

    n/a
    		 -80.01%

    Scores

    Altman Z-Score

    n/a
    		 32.87

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist